Article
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Medical science monitor : international medical journal of experimental and clinical research - 1 Jul 2008
Wysocki Piotr J, Korski Konstanty, Lamperska Katarzyna, Zaluski Jerzy, Mackiewicz Andrzej
Abstract excerpt
BACKGROUND: Docetaxel is a member of the taxoid anticancer agents routinely used in the treatment of high-risk or metastatic breast cancer. A recent study demonstrated that a low response rate to taxane-based neoadjuvant chemotherapy is associated with BRCA1 mutations. Therefore the frequency of BRCA1 mutations in a population of metastatic docetaxel-refractory patients was analyzed. MATERIAL/METHODS: Nineteen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.